news
Global Regulators Are Splitting Over Ashwagandha Leaves and Roots
National health authorities from Denmark to India are tightening rules on ashwagandha, distinguishing between traditional root extracts and cheaper aerial leaves. The shift targets safety questions around thyroid function and varying withanolide potency across retail supplements. It leaves shoppers facing wildly different formulas depending on the country on the label.
National health authorities from Denmark to India are tightening rules on ashwagandha, distinguishing between traditional root extracts and cheaper aerial leaves. The shift targets safety questions around thyroid function and varying withanolide potency across retail supplements. It leaves shoppers facing wildly different formulas depending on the country on the label.
The architecture take
I used to assume every bottle of ashwagandha on the shelf did roughly the same thing to my HPA axis. Then Denmark banned it over thyroid concerns, France started scrutinizing withanolide concentrations, and India's Ministry of Ayush drew a firm line against using aerial leaves instead of traditional root. The split comes down to chemistry. Roots cost more to harvest. Leaves pack higher concentrations of withaferin A at a fraction of the price. When you take leaf extracts to blunt your cortisol response or nudge GABA receptors before bed, you get a completely different alkaloid profile than the classic trials used. I admitted to myself last year that my cheap sleep gummies were doing nothing. I stopped buying generic blends without checking the exact plant part. Expect brands cutting corners with cheap leaf extracts to get squeezed off European shelves, leaving US shoppers guessing what sits in their bedtime capsule.